Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 12/2015

01-12-2015 | Original Article

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas

Authors: Dr. med. Mostafa Farzin, MD, Prof. Dr. med. Michael Molls, PD Dr. med. Sabrina Astner, Ina-Christine Rondak, Dipl.-Stat., Dr. rer. nat. Markus Oechsner, PhD

Published in: Strahlentherapie und Onkologie | Issue 12/2015

Login to get access

Abstract

Background

In 20 patients with high-grade gliomas, we compared two methods of planning for volumetric-modulated arc therapy (VMAT): simultaneous integrated boost (SIB) vs. sequential boost (SEB). The investigation focused on the analysis of dose distributions in the target volumes and the organs at risk (OARs).

Method

After contouring the target volumes [planning target volumes (PTVs) and boost volumes (BVs)] and OARs, SIB planning and SEB planning were performed. The SEB method consisted of two plans: in the first plan the PTV received 50 Gy in 25 fractions with a 2-Gy dose per fraction. In the second plan the BV received 10 Gy in 5 fractions with a dose per fraction of 2 Gy. The doses of both plans were summed up to show the total doses delivered. In the SIB method the PTV received 54 Gy in 30 fractions with a dose per fraction of 1.8 Gy, while the BV received 60 Gy in the same fraction number but with a dose per fraction of 2 Gy.

Results

All of the OARs showed higher doses (Dmax and Dmean) in the SEB method when compared with the SIB technique. The differences between the two methods were statistically significant in almost all of the OARs. Analysing the total doses of the target volumes we found dose distributions with similar homogeneities and comparable total doses.

Conclusion

Our analysis shows that the SIB method offers advantages over the SEB method in terms of sparing OARs.
Appendix
Available only for authorised users
Literature
1.
Cho KH, Kim J-Y, Lee SH et al (2010) Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. Int J Radiat Oncol Biol Phys 78:390–397CrossRefPubMed
2.
Iuchi T, Hatano K, Narita Y et al (2006) Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 64:1317–1324CrossRefPubMed
3.
Prados MD, Wara WM, Sneed PK et al (2001) Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49:71–77CrossRefPubMed
4.
Nieder C, Andratschke N, Wiedenmann N et al (2004) Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome? Strahlenther Onkol 180:401–407CrossRefPubMed
5.
Selker RG, Shapiro WR, Burger P et al (2002) The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51:343–355PubMed
6.
Souhami L, Seiferheld W, Brachman D et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60:853–860CrossRefPubMed
7.
Nakamatsu K, Suzuki M, Nishimura Y et al (2008) Treatment outcomes and dose-volume histogram analysis of simultaneous integrated boost method for malignant gliomas using intensity-modulated radiotherapy. Int J Clin Oncol 13:48–53CrossRefPubMed
8.
9.
Lu SH, Cheng JC, Kuo SH et al (2012) Volumetric modulated arc therapy for nasopharyngeal carcinoma: a dosimetric comparison with TomoTherapy and step-and-shoot IMRT. Radiother Oncol 104:324–330CrossRefPubMed
10.
Shaffer R, Nichol AM, Vollans E et al (2010) A comparison of volumetric modulated arc therapy and conventional intensity-modulated radiotherapy for frontal and temporal high-grade gliomas. Int J Radiat Oncol Biol Phys 76:1177–1184CrossRefPubMed
11.
Roa DE, Schiffner DC, Zhang J et al (2012) The use of RapidArc volumetric-modulated arc therapy to deliver stereotactic radiosurgery and stereotactic body radiotherapy to intracranial and extracranial targets. Med Dosim 37:257–264CrossRefPubMed
12.
Panet-Raymond V, Ansbacher W, Zavgorodni S et al (2012) Coplanar versus noncoplanar intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) treatment planning for fronto-temporal high-grade glioma. J Appl Clin Med Phys 13:3826PubMed
13.
Suzuki M, Nakamatso K, Kanamori S et al (2003) Feasibility study of the simultaneous integrated boost (SIB) method for malignant gliomas using intensity-modulated radiotherapy (IMRT). Jpn J Clin Oncol 33:271–277CrossRefPubMed
14.
Thilmann C, Zabel A, Grosser KH et al (2001) Intensity-modulated radiotherapy with an integrated boost to the macroscopic tumor volume in the treatment of high-grade gliomas. Int J Cancer 96:341–349CrossRefPubMed
15.
n a (2010) The international commission on radiation units and measurements. J ICRU 10(1). doi:10.1093/jicru/ndq001. (Report 83. Oxford University Press)
16.
17.
Sveistrup J, af Rosenschöld PM, Deasy JO et al (2014) Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol 9:44PubMedCentralCrossRefPubMed
18.
Mok G, Gauthier I, Jiang H et al (2015) Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer. Head Neck. doi:10.1002/hed.23649
19.
Matthiesen C, Herman TD, Singh H et al (2015) Dosimetric and radiobiologic comparison of 3D conformal, IMRT, VMAT and proton therapy for the treatment of early-stage glottic cancer. J Med Imaging Radiat Oncol. doi:10.1111/1754-9485.12227
20.
Burnet NG, Jena R, Burton KE et al (2014) Clinical and practical considerations for the use of intensity-modulated radiotherapy and image guidance in neuro-oncology. Clin Oncol (R Coll Radiol) 26:395–406CrossRef
21.
Bansal A, Kapoor R, Singh SK et al (2012) Dosimetric comparison of standard three-dimensional conformal radiotherapy followed by intensity-modulated radiotherapy boost schedule (sequential IMRT plan) with simultaneous integrated boost-IMRT (SIB IMRT) treatment plan in patients with localized carcinoma prostate. Indian J Urol 28:300–306PubMedCentralCrossRefPubMed
22.
Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV (2009) Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73:685–691CrossRefPubMed
23.
Li XA, Wang JZ, Jursinic PA et al (2005) Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 61:1251–1257CrossRefPubMed
24.
Dogan N, King S, Emami B et al (2003) Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing. Int J Radiat Oncol Biol Phy 57:1480–1491CrossRef
25.
Chen SW, Yang SN, Liang JA et al (2005) Comparative dosimetric study of two strategies of intensity-modulated radiotherapy in nasopharyngeal cancer. Med Dosim 30:219–227CrossRefPubMed
26.
Baisden JM, Sheehan J, Reish AG et al (2011) Helical tomotherapy simultaneous integrated boost provides a dosimetric advantage in the treatment of primary intracranial tumors. Neurol Res 33:820–824CrossRefPubMed
27.
Prokic V, Wiedenmann N, Fels F et al (2013) Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys 85:264–270CrossRefPubMed
28.
Yang W, Jones R, Read P et al (2011) Standardized evaluation of simultaneous integrated boost plans on volumetric modulated arc therapy. Phys Med Biol 56:327–339CrossRefPubMed
29.
Lee AW, Kwong DL, Leung SF et al (2002) Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys 53:75–85CrossRefPubMed
30.
Marks JE, Baglan RJ, Prassad SC, Blank WF (1981) Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 7:243–252CrossRefPubMed
31.
Ruben JD, Dally M, Bailey M et al (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65:499–508CrossRefPubMed
Metadata
Title
Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas
Authors
Dr. med. Mostafa Farzin, MD
Prof. Dr. med. Michael Molls
PD Dr. med. Sabrina Astner
Ina-Christine Rondak, Dipl.-Stat.
Dr. rer. nat. Markus Oechsner, PhD
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 12/2015
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0888-1

Other articles of this Issue 12/2015

Strahlentherapie und Onkologie 12/2015 Go to the issue

Letter to the Editor

Comment on Dornoff et al.: Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck

Original Article

Stereotactic interstitial brachytherapy for the treatment of oligodendroglial brain tumors

Original Article

Genehmigungsverfahren klinischer Studien im Bereich der Radioonkologie

Literatur kommentiert

Hodgkin-Lymphom in Kindheit oder Jugend: Keine niedrigere Mutterschaftsrate nach Bestrahlungen außerhalb des Beckens

Original Article

Radiotherapy for benign achillodynia

Letter to the Editor

Reply to: Comment on Dornoff et al.: re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck